Eli Lilly and Company (LLY)
| Market Cap | 325.02B |
| Revenue (ttm) | 28.54B |
| Net Income (ttm) | 6.24B |
| Shares Out | 952.35M |
| EPS (ttm) | 6.90 |
| PE Ratio | 49.67 |
| Forward PE | 39.06 |
| Dividend | $4.07 (1.19%) |
| Ex-Dividend Date | Feb 14, 2023 |
| Volume | 778,262 |
| Open | 342.00 |
| Previous Close | 340.69 |
| Day's Range | 340.69 - 343.37 |
| 52-Week Range | 276.83 - 375.25 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 388.37 (+13.81%) |
| Earnings Date | Apr 27, 2023 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal... [Read more]
Financial Performance
In 2022, LLY's revenue was $28.54 billion, an increase of 0.79% compared to the previous year's $28.32 billion. Earnings were $6.24 billion, an increase of 11.88%.
Financial StatementsAnalyst Forecast
According to 30 analysts, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $388.37, which is an increase of 13.81% from the latest price.
News
Final trades: Intel, JPMorgan, Eli Lilly & Amgen
The final trades of the week. With CNBC's Tyler Mathisen and the Fast Money traders, Steve Grasso, Courtney Garcia, Tim Seymour and Guy Adami.
Drugs for obesity are a massive market, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to discuss obesity drugs with CNBC's Tyler Mathisen and the Fast Money traders.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Alzheimer's Blood Test That Could Help Diagnose Disease Earlier Is Being Developed By Eli Lilly And Roche
If approved, the test could streamline the diagnostic journey and help patients get earlier access to future Alzheimer's treatments, Roche said.
Eli Lilly Is Priced for Perfection in the Obesity Market
The company has outperformed its pharma peers in recent years, but its valuation leaves little room for error.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
INDIANAPOLIS , March 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research ...
Eli Lilly suffers setback in Alzheimer's treatment plans
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the setback Eli Lilly is facing for one of its Alzheimer's treatment drugs while it looks to a phase 3 trial for another drug.
Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study
Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.
Eli Lilly Alzheimer's treatment solanezumab failed to slow disease progression
Solanezumab's failure is a blow to efforts to treat Alzheimer's in people who have not yet shown clinical symptoms.
Lilly's drug aimed at preventing Alzheimer's fails
Eli Lilly & Co. said late Wednesday that a drug aimed at preventing Alzheimer's disease before symptoms start has failed to slow down cognitive decline in healthy older adults at risk of developing th...
Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
Results showed solanezumab did not slow cognitive decline in preclinical Alzheimer's disease or reduce risk of progression to symptomatic Alzheimer's disease Solanezumab targets soluble amyloid beta, ...
Eli Lilly Drug Fails to Prevent Alzheimer's in Study
The drug, which had failed testing whether it could slow Alzheimer's in people with the disease, was no better than placebo at averting the condition.
US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes
The application is based on phase III results from the DINAMO trial showing Jardiance® (empagliflozin) tablets significantly reduced A1c (a marker of average blood sugar) versus placebo in participant...
Eli Lilly's Insulin Decision Puts Others in Hot Seat
The drugmaker's plan moves the spotlight to industry middlemen, who face a barrage of investigations.
Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer
Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study
The findings, from the COORDINATE-Diabetes trial, demonstrate the benefit of clinic-level educational interventions, including a focus on coordinating care between cardiology and diabetes care provide...
7 High-Growth Stocks for ESG-Oriented Investors
Generally, a perception exists that supporting environmental, social, and governance ( ESG) initiatives may lead to expansion and profitability erosion, though the enthusiasm toward the following hig...
Best Buy, Eli Lilly, Salesforce: Stocks That Defined the Week
Here are seven major companies whose stocks moved on the week's news.
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade , regardless of Ki-67 score Approval supported by four-year data from the mo...
NVS vs. LLY: Which Stock Is the Better Value Option?
NVS vs. LLY: Which Stock Is the Better Value Option?
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli Lill...
Biden says other companies will slash insulin prices after Eli Lilly move
U.S. President Joe Biden said on Wednesday that other pharmaceutical companies will have to lower their insulin prices in the wake of Eli Lilly's decision to slash its prices for the popular diabetes ...